SCHEMBL4775223

SCHEMBL4775223

O=C(NCc1ccc(C(F)(F)F)nc1)c1ccc(NS(=O)(=O)CCc2cccc(Cl)c2Cl)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.47
ITK Q08881 2/20 0.41
SCN3A Q9NY46 8/20 0.41
MAPT P10636 3/20 0.41
TP53 P04637 1/20 0.40
SCN1A P35498 2/20 0.39
SCN5A Q14524 2/20 0.39
SCN9A Q15858 2/20 0.39
SCN2A Q99250 2/20 0.39
SCN8A Q9UQD0 2/20 0.39
SCN10A Q9Y5Y9 2/20 0.39
KCNH2 Q12809 1/20 0.39
KMT2A Q03164 3/20 0.39
LMNA P02545 2/20 0.39
MEN1 O00255 2/20 0.39
NPSR1 Q6W5P4 2/20 0.38
TRPV1 Q8NER1 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
RORC P51449 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4775016 0.94 DGAT2 (0.46) DGAT2ITKSCN3AMAPTTP53
SCHEMBL4776602 0.91 DGAT2 (0.44) DGAT2ITKSCN3AMAPTTP53
SCHEMBL4767775 0.89 ROCK2 (0.47) DGAT2ITKSCN3AMAPTLMNA
SCHEMBL4767854 0.88 MAPT (0.46) DGAT2ITKSCN3AMAPTTP53
SCHEMBL4776574 0.86 P2RX7 (0.42) DGAT2TRPV1P2RX7
SCHEMBL4776751 0.84 P2RX7 (0.41) DGAT2MAPTKMT2ALMNAMEN1
SCHEMBL4768151 0.81 MAPT (0.49) DGAT2ITKSCN3AMAPTTP53
SCHEMBL5572196 0.80 PPARA (0.42) DGAT2ITKSCN3AMAPTKMT2A
SCHEMBL4775232 0.79 GAA (0.47) DGAT2ITKSCN3AMAPTTP53
SCHEMBL4776657 0.79 LMNA (0.41) MAPTLMNAP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 DGAT2 3173/4885ITK 4081/4885SCN3A 3406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.